Skip to main content

Table 2 Overview of treatment emergent adverse events (TEAEs)

From: Phase 1/2 study of topical submicron particle paclitaxel for cutaneous metastases of breast cancer

Adverse events All doses (n = 23)
All Grades n (%) Grades 1–2 n (%) Grades 3–4 n (%)
Skin lesion 7 (30%) 6 (26%) 1 (4%)
Application site pain 7 (30%) 7 (30%)
Pruritus 7 (30%) 7 (30%)
Application site hemorrhage 6 (26%) 5 (22%) 1 (4%)
Hyperglycemia 5 (22%) 5 (22%)
Headache 4 (17%) 3 (13%) 1 (4%)
Aspartate aminotransferase increased 4 (17%) 4 (17%)
Fatigue 3 (13%) 2 (9%) 1 (4%)
Nausea 3 (13%) 2 (9%) 1 (4%)
Cough 3 (13%) 3 (13%)
Blood alkaline phosphatase increased 3 (13%) 3 (13%)
Hypomagnesaemia 3 (13%) 3 (13%) -
  1. TEAEs that were observed in greater than 10% of all subjects (n ≥ 3) are listed in table
  2. Adverse Event is coded using MedDRA version 20.1; Grade 1—Mild, Grade 2—Moderate, Grade 3—Severe, Grade 4—Life threatening
  3. TEAE treatment emergent adverse events